Key facts
- This page summarizes Chaim Hurvitz's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Sep 2025, 15:35.
Chaim Hurvitz - 09 Apr 2025 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)
- Reporting relationship
- Director
- Issuer ticker
- NRXP
- Reported as of
- 09 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Sep 2025, 15:35:00 UTC
- Prior SEC filing
- 25 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chaim Hurvitz
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chaim Hurvitz filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 10 Sep 2025.
Change
- Previous filing in this sequence was filed on 25 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001630542
Primary reporting owner
Hurvitz Chaim
- Relationship
- Director
- Address
- C/O NRX PHARMACEUTICALS, INC., 1201 ORANGE AVENUE, SUITE 600, WILMINGTON
- Signature
- /s/ Chaim Hurvitz
- Signature date
- 10 Sep 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NRXP
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 09 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.73
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.